Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine Supplementation in Glioblastoma Multiforme
NCT02017249Phase 1Completed
- Sponsor
- Inova Health System
- Start
- Mar 2014
- Primary completion
- Sep 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in glioblastoma multiforme (GBM) comparing Arginine with Placebo (2 arms). Primary endpoint: Change in immune function through arginine supplementation at Day 8. Started Mar 2014; status: completed.
02
Drugs
arginine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02017249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017249.